Leber\'s Hereditary Optic Neuropathy Drug Market
Leber\'s Hereditary Optic Neuropathy Drug Market
Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Leber\'s Hereditary Optic Neuropathy Drug Market
Size and Growth
The Leber's Hereditary Optic Neuropathy (LHON) drug market is experiencing significant growth, driven by increased prevalence and advancements in gene therapies. The market size is projected to reach approximately $XX million by 2027, with emerging treatments addressing unmet needs and fostering competitive dynamics among pharmaceutical companies focused on rare genetic disorders. Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Alkeus Pharmaceuticals, Inc.
◍ Biovista Inc.
◍ GenSight Biologics S.A.
◍ Ixchel Pharma, LLC
◍ Khondrion BV
◍ Spark Therapeutics, Inc.
◍ Stealth BioTherapeutics Inc.
The competitive landscape for Leber's Hereditary Optic Neuropathy (LHON) includes companies like Alkeus Pharmaceuticals, GenSight Biologics, and Stealth BioTherapeutics, focusing on therapies targeting mitochondrial dysfunction. These firms drive innovation and market growth through collaborations, clinical trials, and advancements in gene therapies.
- Alkeus Pharmaceuticals: Estimated revenue not disclosed.
- GenSight Biologics: €4.7 million in 2022.
- Stealth BioTherapeutics: $10 million in 2022.
Request Sample Report
Market Segmentation
By Application
Hospital
Clinic
Others
Request Sample Report
By Product
Elamipretide
GS-011
IXC-201
KH-176
Others
Market Growth
Request Sample Report
$ X Billion USD
